The use of human tumour cell lines in the discovery of new cancer chemotherapeutic drugs

Expert Opinion on Drug Discovery

Volumn 3, Issue 2, 2008, Pages 153-161

  Baguley, Bruce C ^a   Marshall, Elaine S ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Anticancer drug; Differentiation; Melanoma; Passaging; Senescence; Stem cell; Tumour cell line; Tumour stem cell

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPAMINE;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER STEM CELL; CELL AGING; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL PROLIFERATION; CELL REGENERATION; DISEASE MODEL; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; EPIGENETICS; GENE IDENTIFICATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MEDICAL LITERATURE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 39549120216     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.2.153     Document Type: Review

References (59)

1. Finkel T, Serrano M, Blasco MA. The common biology of cancer and ageing. Nature 2007;448:767-74
2. Goldin A, Venditti JM, MacDonald JS, et al. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer 1981;17:129-42
3. Finlay GJ, Baguley BC, Wilson WR. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem 1984;139:272-7
4. Finlay GJ, Wilson WR, Baguley BC. Comparison of in vitro activity of cytotoxic drugs towards human carcinoma and leukemia cell lines. Eur J Cancer Clin Oncol 1986;22:655-62
5. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-33
6. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 1995;34:91-109
7. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92
8. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757-66
9. Lee JK, Havaleshko DM, Cho H, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 2007;104:13086-91
10. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006;2:689-700
11. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007;6:834-48
12. Bridges AJ. The epidermal growth factor receptor family of tyrosine kinases and cancer: can an atypical exemplar be a sound therapeutic target? Curr Med Chem 1996;3:211-26
13. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006;5:649-59
14. Baguley BC, Marshall ES, Holdaway KM, et al. Inhibition of growth of primary human tumor cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases. Eur J Cancer 1998;34:1086-90
15. Baguley BC, Marshall ES. In vitro modeling of human tumor behavior in drug discovery programmes. Eur J Cancer 2004;40:794-801
16. Burger H, den Bakker MA, Kros JM, et al. Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesilate target genes. Cancer Biol Ther 2005;4:1270-4
17. Grothey A. Biological therapy and other novel therapies in early-stage disease: are they appropriate? Clin Cancer Res 2007;13:6909S-6912S
18. Stubbs MC, Armstrong SA. Therapeutic implications of leukemia stem cell development. Clin Cancer Res 2007;13:3439-42
19. Sell S, Leffert HL. An evaluation of cellular lineages in the pathogenesis of experimental hepatocellular carcinoma. Hepatology 1982;2:77-86
20. Moore KA, Lemischka IR. Stem cells and their niches. Science 2006;311:1880-5
21. Baguley BC. Tumor stem cell niches: a new functional framework for the action of anticancer drugs. Recent Pat Anti Cancer Drug Discov 2006;1:121-7
22. Hill RP, Perris R. 'Destemming' cancer stem cells. J Natl Cancer Inst 2007;99:1435-40
23. Lou H, Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007;26:1357-60
24. Adams GB, Chabner KT, Alley IR, et al. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 2006;439:599-603
25. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449:1003-7
26. Bendall SC, Stewart MH, Menendez P, et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro Nature 2007;448:1015-21
27. Lee MG, Villa R, Trojer P, et al. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitylation. Science 2007;318:447-50
28. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007;21:525-30
29. Psaila B, Kaplan RN, Port ER, Lyden D. Priming the 'soil' for breast cancer metastasis: the premetastatic niche. Breast Dis 2006;26:65-74
30. Cairns J. Cancer and the immortal strand hypothesis. Genetics 2006;174:1069-72
31. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science 1998;280:1036-7
32. Baguley BC, Marshall ES, Christmas TI. Cultures of surgical material from lung cancers. A kinetic approach. In: Lung Cancer. Molecular Pathology Methods and Reviews (Volume 1). Driscoll B, editor. Totowa, New Jersey: Humana Press; 2002. p. 527-44
33. Wilson GD, McNally NJ, Dische S, et al. Measurement of cell kinetics in human tumors in vivo using bromodeoxyuridine in corporation and flow cytometry. Br J Cancer 1988;58:423-31
34. Watson JV. Tumor growth dynamics. Br Med Bull 1991;47:47-63
35. Baguley BC, Marshall ES, Whittaker JR, et al. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumor cells cultured from patients with ovarian cancer. Eur J Cancer 1995;31A:230-7
36. Torres EM, Sokolsky T, Tucker CM, et al. Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science 2007;317:916-24
37. Zheng X, Shen G, Yang X, Liu W. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res 2007;67:3691-7
38. Parmar J, Marshall ES, Charters GA, et al. Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines. Oncol Res 2000;12:149-55
39. Noble M, Dietrich J. The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity. Trends Neurosci 2004;27:148-54
40. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 2007;6:2332-8
41. Widlund HR, Fisher DE. Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 2003;22:3035-41
42. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006;20:2149-82
43. Xu W, Gong L, Haddad MM, et al. Regulation of microphthalmia-associated transcription factor MITF protein levels by association with the ubiquitin-conjugating enzyme hUBC9. Exp Cell Res 2000;255:135-43
44. Zhang H. Molecular signaling and genetic pathways of senescence: its role in tumorigenesis and ageing. J Cell Physiol 2007;210:567-74
45. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2A locus, p14[ARF], participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998;17:5001-14
46. Greet EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005;24:7410-25
47. Ha L, Ichikawa T, Anver M, et al. ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci USA 2007;104:10968-73
48. Kiselyov AS. Targeting the hedgehog signaling pathway with small molecules. Anticancer Agents Med Chem 2006;6:445-9
49. van Es JH, Clevers H. Notch and Wnt inhibitors as potential new drugs for intestinal neoplastic disease. Trends Mol Med 2005;11:496-502
50. Katoh M. Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol Ther 2006;5:1059-64
51. Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007;13:4042-5
52. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445:851-7
53. Zhao L, Marshall E, Kelland LR, Baguley BC. Evidence for the involvement of p38 MAPK in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid [DMXAA]. Invest New Drugs 2007;25:271-6
54. Xue W, Zender L, Miething C, et al. Senescence and tumor clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-60
55. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61
56. Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006;25:409-16
57. Maeda S, Kamata H, Luo JL, et al. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005;121:977-90
58. Basse B, Baguley BC, Marshall ES, et al. Modeling cell death in human tumor cell lines exposed to the anticancer drug paclitaxel. J Math Biol 2004;49:329-57
59. Basse B, Baguley BC, Marshall ES, et al. Modeling cell population growth with applications to cancer therapy in human tumor cell lines. Prog Biophys Mol Biol 2004;85:353-68